Safety, risks, and what has actually gone wrong

The risk profile is not uniform across this category. At the better-studied end, the PRP meta-analyses reported no serious adverse events attributable to treatment, and the polynucleotide review described side effects as generally mild and transient. At the other end, the critical review literature on unproven cell-based interventions documents infection, immune rejection and tumour formation, and neurological complications have been reported and reviewed separately. The single largest modifiable risk is not the biology — it is agreeing to a procedure without knowing what is in it, who is accountable, and who will manage a complication after you have flown home.

What the better-studied modalities report

It is worth stating the reassuring part precisely, because vagueness in either direction is unhelpful. The systematic review and meta-analysis covering 27 controlled PRP trials in 1,117 subjects reported no serious adverse events related to PRP injection or to the control treatments^[4]. The systematic review of polynucleotides in aesthetic medicine, covering nine studies and 219 patients, described side effects as generally mild and transient^[5].

Those are real findings, and they are bounded ones. Both describe short follow-up in modest numbers of patients under study conditions, which is not the same as long-term safety data from routine practice. Absence of serious events in 1,117 people constrains how common a serious event can be; it does not exclude rare ones.

What has gone wrong with unproven cell-based interventions

The literature here is about cell-based interventions offered outside research frameworks, largely for serious conditions rather than aesthetic ones. It is nonetheless the relevant evidence, because the mechanism of harm follows the material and the oversight rather than the indication.

A critical review of international stem cell tourism reports that stem cell therapies offered in this market are associated with complications including infection, rejection and tumorigenesis, that the clinics involved are predominantly located in low- and middle-income countries with lighter regulation, and that they generally do not provide even basic travel health information to the patients they recruit^[1]. A review focused on neurology describes a rising pattern of patients with incurable conditions seeking cell preparations outside clinical research, and the neurological complications reported from those activities^[2]. Clinical commentary has characterised the sector as one where the corrective has to come from regulators, professional bodies and physicians together^[3].

The risk that travel adds

A patient treated locally has a route back to the person who treated them. A patient who flew for the procedure often does not, and this is a structural risk rather than a biological one. The stem cell tourism review notes that patients place themselves at risk both of receiving an unproven treatment and of travel-related illness, and that pre-travel health advice is largely absent from the clinics’ own materials^[1].

A domestic clinician asked to manage a complication needs to know what was administered. “Exosomes” is not an answer to that question — as the exosome page sets out, isolation methods and source material vary between suppliers, and reviews identify that variability as an unresolved problem in the field^[6]. Before travelling, get in writing what the material is, where it came from, and what was done to it.

Where the pressure comes from

It helps to understand why the marketing is as confident as it is. A bioethics analysis of stem cell marketing in South Korea and the United States describes an industry that has offered cell-based interventions in the absence of conclusive evidence of safety and efficacy for over a decade, sustained by a combination of funding initiatives, permissive legal structures and belief systems that lent the practice legitimacy^[7]. That is the environment in which a patient is being asked to make a judgement, and it is a reason to want documents rather than reassurance.

Contraindications and disclosure

Any injectable procedure has general contraindications that apply regardless of what is being injected: active infection at the site, anticoagulant or antiplatelet therapy, bleeding disorders, pregnancy and breastfeeding, active autoimmune disease under treatment, and a history of keloid formation. Autologous preparations add a harvest procedure with its own risks. Products derived from non-human sources — PDRN is manufactured from salmon DNA — raise questions for patients with relevant allergies.

None of that is a substitute for examination, and this site cannot tell you whether any of it applies to you. It is a list of things a consultation should cover, and their absence from a consultation is itself informative.

Written by the Stem Cell Seoul editorial team and medically reviewed by a Korean Board-Certified Dermatologist (AAD International Fellow · ASLMS member). Last reviewed 2026-08-30.